ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INCY Incyte Corporation

52.84
0.79 (1.52%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Incyte Corporation NASDAQ:INCY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.79 1.52% 52.84 52.04 53.50 53.98 51.75 51.87 3,577,694 00:56:34

Incyte to Report Second Quarter Financial Results

12/07/2018 1:00pm

Business Wire


Incyte (NASDAQ:INCY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Incyte Charts.

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its second quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 31, 2018.

The schedule for the press release and conference call/webcast is as follows:

         

Q2 2018 Press Release: July 31, 2018 at 7:00 a.m. ET

Q2 2018 Conference Call: July 31, 2018 at 8:00 a.m. ET

Domestic Dial-In Number: 877-407-3042

International Dial-In Number:

201-389-0864

Conference ID Number: 13681303  

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13681303.

The live webcast with slides can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Incyte CorporationInvestorsMichael Booth, DPhil, +1 302-498-5914mbooth@incyte.comorMediaCatalina Loveman, +1 302-498-6171cloveman@incyte.com

1 Year Incyte Chart

1 Year Incyte Chart

1 Month Incyte Chart

1 Month Incyte Chart

Your Recent History

Delayed Upgrade Clock